探讨生长抑素受体（somatostatin receptor ，SSTR）亚型SSTR2A、SSTR5与表皮生长因子受体（epidermal growth factor receptor, EGFR）在非小细胞肺癌(nonsmall cell lung cancer，NSCLC)组织中的异常表达及其临床意义。方法: 用免疫组化(SP 法)检测 SSTR2A、SSTR5 和EGFR 3种蛋白在62例 NSCLC 组织标本和 7 例癌旁肺组织标本中的表达情况，并进行预后随访。结果: 在 62 例 NSCLC 组织中，SSTR2A蛋白阳性表达30例，占 48.3%；SSTR5阳性表达44例，占70.9%。SSTR2A、SSTR5 蛋白表达与 NSCLC的TNM分期有密切相关（P<0.05），但与 NSCLC 患者的年龄、性别、吸烟与否、病理类型、肿瘤大小和淋巴结转移均无明显相关（P>0.05）。同组中，EGFR蛋白在癌旁肺组织中无一例表达，而在 NSCLC 组织中有 35例阳性，占 56.4%；EGFR 蛋白的表达与NSCLC患者的年龄、性别、吸烟与否、肿瘤组织类型、肿瘤大小、TNM分期、病理分级及淋巴结转移均无显著差异（P>0.05）。SSTR2A、SSTR5 蛋白表达与 EGFR蛋白的表达呈负相关关系。SSTR2A、SSTR5 蛋白阳性表达者的3年生存率分别为64.5%和65.9%,阴性表达者为45.2%和22.2%,两者之间差异显著(P<0.05)；EGFR蛋白阳性表达者的3年生存率为30.8%,阴性表达者为69.4%,两者之间差异显著(P<0.05)；结论: SSTR2A、SSTR5 和EGFR的表达能提示非小细胞肺癌的生物学行为，三者的联合检测对非小细胞肺癌淋巴结转移、病理分期及预后的评估有临床意义。

To investigate the expression of somatostatin receptors (SSTR) subtypes (SSTTR2A, and SSTR5) and epidermal growth factor receptor (EGFR) in nonsmall cell lung cancer (NSCLC) and their clinical relevance. Methods: The expressions of SSTR2A, SSTR5, and EGFR in 62 NSCLC specimens and 7 adjacent normal lung tissues were examined using immunohistochemical method (SP). All patients were followed up in this study. Results: The positive rates of SSTR2A and SSTR5 in the 62 specimens were 48.3% (30 cases) and 70.9% (44 cases), respectively. The positive rates of SSTR2A and SSTR5 were closely related to TNM stage (P<0.05), but not to patients' ages, sexes, smoking history, pathological types, tumor sizes, and lymph metastases (P>0.05). In the same group, EGFR expressed in 56.4% (35 cases) of NSCLC specimens, but was not expressed in the 7 normal spesimens. The positive rate of EGFR was not related to the ages, sexes, smoking history, histological types, tumor sizes, TNM stages, pathological classification, and lymph metastases (P>0.05). There was a negative correlation between the EGFR expression with the expression of SSTR2A and SSTR5 in NSCLC tissues. The 3year survival rates were 64.5% and 65.9% in patients positive of SSTR5 and SSTR2A, respectively; and were 45.2% and 22.2% for those negative of SSTR5 and SSTR2A, respectively (P<0.05). The 3year survival rate was 30.8% for patients positive of EGFR protein and 69.4% for those negative of it (P<0.05). Conclusion: The expressions of SSTR2A, SSTR5, and EGFR can reflect the biology behavior of lung cancer, and the examination of them may be helpful for evaluation of the lymph node metastases, pathological classification, and prognosis of NSCLC.

R373.9 R730.5

山东省科技攻关项目（No.2004GG3202017）